Muscle-Specific Promoters for Gene Therapy.

Area of Science:

• Biomedical Engineering
• Molecular Biology
• Genetics

Background:

• Genetic diseases cause numerous muscular disorders, necessitating advanced treatments.
• Gene replacement therapy offers a promising strategy by delivering functional genes via viral vectors.
• Effective therapy requires precise control over gene expression in target muscles.

Purpose of the Study:

• To review the development and optimization of muscle-specific promoters for gene therapy.
• To explore synthetic promoter engineering and viral vector components for tissue-specific expression.
• To provide current information on clinical and preclinical gene therapy trials using these promoters.

Main Methods:

• Focus on muscle-specific promoters derived from skeletal muscle α-actin, muscle creatine kinase, and desmin genes.
• Analysis of current approaches for engineering synthetic muscle-specific promoters.
• Discussion of viral vector elements influencing tissue-specific gene delivery.

Main Results:

• Significant progress has been made in designing regulatory sequences for high, robust transgene expression in skeletal muscle, diaphragm, and heart.
• Engineered promoters demonstrate limited activity in non-target tissues, enhancing safety.
• Up-to-date information on clinical and preclinical trials is presented.

Conclusions:

• Muscle-specific promoters are critical for the efficacy and safety of gene replacement therapies for muscular disorders.
• Continued development of these promoters and viral vectors will advance gene therapy applications.
• The reviewed information supports the ongoing progress in clinical gene therapy for muscle diseases.